Dementia, drug delivery and in vitro diagnostics benefit from UK Biomedical Catalyst funding boost
This article was originally published in Clinica
Executive Summary
The Biomedical Catalyst, a £180 million ($288 million) public funds pot launched earlier this year by the UK government as part of an initiative to galvanise growth in the life sciences sector, has pumped £22.9 million into a range of early- and late-stage projects led by SMEs.